HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110

Benzinga · 1d ago
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $110.